Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Is Hormel Foods Corporation (HRL) the Best Vegan Stock to Buy According to Hedge Funds?

We recently compiled a list of the 7 Best Vegan Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Hormel Foods Corporation (NYSE:HRL) stands against the other vegan stocks.

Vegan food consists of products that are entirely free of animal ingredients or by-products, including meat, poultry, fish, dairy, eggs, honey, and other animal-derived substances. Veganism is both a dietary and lifestyle choice aimed at avoiding animal exploitation while promoting ethical, environmental, and health benefits. That said, vegan and plant-based products appeal to a much broader audience than just those avoiding meat and animal products. This is especially true for meat substitutes. Pat Brown, founder of Impossible Foods, believes that vegetarians are not the primary audience for these products, which are designed to closely mimic the taste and texture of meat. Instead, meat substitutes are aimed at meat eaters, helping them transition to a plant-based diet more easily by offering familiar flavors and experiences.

Additionally, a study published by the Journal of the American Medical Association (JAMA) found that individuals who follow a vegan diet have a higher life expectancy than those on a meat-based diet. This has led health-conscious consumers to embrace vegan food, positively impacting leading plant-based food stocks. Another study by researchers at Oxford’s Martin School found that a global shift toward diets rich in fruits and vegetables and less reliant on meat could potentially prevent around 8 million deaths by 2050. This dietary transition could also save approximately $1.5 trillion in climate-related costs and reduce greenhouse gas emissions by over 60%. Studies consistently show that Gen Z is particularly interested in plant-based diets, driving companies to develop products tailored to this key demographic. Plant-based diets also offer substantial environmental benefits.

Veganism extends beyond just food—clothing made without animal products also qualifies as vegan fashion. More specifically, vegan fashion often refers to items typically made from plant-based or synthetic alternatives to animal materials. In 2022, the global market for non-animal leather clothing and accessories reached approximately $41 billion, with the United States as the largest market. Footwear is a key segment in this shift, where leather has long been valued for quality in both sneakers and formal shoes. To meet growing demand for animal-free options, brands are innovating. In 2021, Adidas introduced a Stan Smith sneaker made from a mushroom-based leather alternative, and has also collaborated with vegan fashion leader Stella McCartney on other vegan footwear.

Despite rising awareness of animal welfare in fashion, this hadn’t consistently translated into consumer behavior until more recently. A new global YouGov survey reveals that over a quarter (27%) of people now actively avoid animal-based fashion. The poll also shows strong public support for cruelty-free fashion, with 70% of Americans agreeing that fashion companies should reduce their use of animal-derived materials, invest in alternatives, and transition to sustainable, animal-friendly materials.

According to Fortune Business Insights, the global vegan food market was valued at $33.14 billion in 2023 and is expected to grow to $37.37 billion in 2024. By 2032, it is projected to reach $103.00 billion, with a compound annual growth rate (CAGR) of 13.51% over the forecast period. Bloomberg Intelligence further projects that the plant-based food market could account for 7.7% of the global protein market by 2030, with an estimated value exceeding $162 billion. Moreover, meat alternatives are set to capture a significant portion of the plant-based food market through 2030. If this sector mirrors the growth of plant-based milk, Bloomberg Intelligence projects that it could expand from its current $4.2 billion to $74 billion over the next decade.

Our Methodology

We first compiled a list of vegan stocks by sifting through financial media reports. We selected the following vegan stocks based on hedge fund sentiment toward each company. The sentiment data was sourced from Insider Monkey’s database, which tracks 912 elite hedge funds as of the end of Q2 2024. The list is organized in ascending order, based on the number of hedge fund investors in each firm.

At Insider Monkey, we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

A close-up of a hand cutting fresh turkeys, revealing the perishable products of the company.

Hormel Foods Corporation (NYSE:HRL)

Number of Hedge Fund Holders: 31

Hormel Foods Corporation (NYSE:HRL) is a global branded food company operating in over 80 countries, with a portfolio featuring iconic brands like Planters, Skippy, SPAM, Hormel Natural Choice, and Justin’s. Among its offerings, the Happy Little Plants brand caters to consumers seeking plant-based protein alternatives, targeting vegan and vegetarian markets.

In Q3 2024, Hormel Foods Corporation (NYSE:HRL) reported net sales of $2.90 billion, a 2.2% year-over-year decline, largely due to weaker performance in its Retail and International segments. The Retail segment, including Justin’s, experienced a 7% drop in sales, primarily driven by lower volumes and pricing for whole bird turkeys and disruptions at its Suffolk, Virginia facility. Despite these challenges, Hormel Foods Corporation (NYSE:HRL) generated $218 million in operating cash flow, reflecting strong liquidity, and reduced capital expenditures compared to the previous year, showcasing effective cost management. The company also returned $155 million to shareholders through dividends, continuing its 96-year streak of uninterrupted payouts.

Stephens initiated coverage on the food company on October 3, giving it an Equal Weight rating with a $31 price target. The firm acknowledged Hormel’s leadership in its core product categories and its focus on expanding branded, value-added products. However, it also highlighted operational challenges, particularly in the Turkey segment, as key obstacles for the company.

Overall HRL ranks 4th on our list of the best vegan stocks to buy according to hedge funds. While we acknowledge the potential of HRL as an investment, our conviction lies in the belief that certain AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than HRL but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None. This article is originally published at Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

Penicillin Changed the World. This Drug Could Too

This Clinical-stage Biotech Company is Taking a Revolutionary Approach to Eradicating Many Respiratory Viruses Including a single drug to treat COVID, RSV, FLU and even Monkey-pox!

This is a clinical-stage, global leader in broad-spectrum antiviral nanomedicines who is developing therapeutic drugs that work safely and effectively, even against emerging variants!

A novel broad-spectrum antiviral

NV-387,  a drug that  treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials in healthy subjects with no reported adverse events, even at the highest and repeated dosages. Remarkably, the company has been able to develop NV-387 for oral administration already, as well as for injectable and inhalation formulations to enable many modes of use. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.

Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants. Why? Because  no matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective even as the virus mutates to generate variants.

Click to continue reading…